Retinopathy-associated alpha-interferon-ribavirin therapy and the importance of the electro-oculogram: A case report;Rétinopathie à l'interféron-α associé à la ribavirine: Atteinte de l'électro-oculogramme: À propos d'un cas

Journal Francais d'Ophtalmologie

Volumn 27, Issue 3, 2004, Pages 257-262

  Crochet, M ^a   Ingster Moati, I ^b   Even, G ^c   Dupuy, P ^d  

^a Cabinet Ophtalmologique   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c Cabinet Ophtalmologique   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Alpha interferon; Electro oculogram; Retinopathy; Ribavirin

Indexed keywords

ALPHA INTERFERON; LEVOTHYROXINE; RIBAVIRIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG WITHDRAWAL; ELECTROOCULOGRAM; ELECTRORETINOGRAM; EVOKED VISUAL RESPONSE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HEPATITIS C; HUMAN; HYPOTHYROIDISM; RETINA HEMORRHAGE; RETINOPATHY; VISUAL DISORDER; VISUAL FIELD;

EID: 1842459212     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(04)96127-X     Document Type: Article

References (20)

1. Halfon P, Cartouzou G, Bourliere M. Les génotypes du virus de l'hépatite C, intérêts en pratique, Hépato Gastro, 1997;14:295-303.
2. Pawlatasky JM. Le virus de l'hépatite C. Médecine/Sciences, 2002; 18:303-14.
3. Jain K, Lam WC, Waheeb S, Thai Q, Heathcore J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol, 2001;85:1171-3.
4. Thoraval F. Épidémiologie de l'hépatite C. Médecine/Sciences, 2002;18:315-24.
5. Boyer N, Marcellin P. Traitement de l'hépatite C. Médecine/Sciences, 2002;18:342-452.
6. Poynard T, Mc Hutchison J, Manns M, Trepo C, Lindsay K, Goodman Z et al. Impact of pegylated interferon alfa-2b and ribavirin on the liver fibrosis in patients with chronic hepatitis C. Gastroenterology, 2002;122:1303-13.
7. Guyer D, Tiedeman J, Yannuzzi LA, Slakter JS, Parke D, Kelley J et al. Interferon associated retinopathy. Arch Ophthalmol, 1993; 111:350-6.
8. Hayasaka S, Nagaki Y, Matsumoto M, Sato S. Interferon associated retinopathy. Br J Ophthalmol, 1998;82:323-5.
9. Hejny C, Sternberg P, Lawson DH, Greiner K, Aaberg TA Jr. Retinopathy Associated with High Dose Interferon Alpha 2b Therapy. Am J Ophthalmol, 2001;131:782-7.
10. Saito H, Ebinuma H, Nagata H, Inagaki Y, Saito Y, Wakabayashi K et al. Interferon associated retinopathy in a uniform regimen of natural interferon alpha therapy for chronic hepatitis C. Liver, 2001;21:192-7.
11. Emonet-Mercier E, Touraud JP, Tsan P, Chapard J, Dalac S, Lambert D. Faut-il imposer une surveillance ophtalmologique chez les patients sous interféron Alpha? Ann Dermatol Venerol, 2001; 128:257-60.
12. Schulman JA, Liang C, Kooragalaya LM, King J. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology, 2003;110:437-42.
13. Tokai R, Ikeda T, Miyaura T, Sato K Interferon associated retinopathy and cystoid edema. Arch Ophthalmol, 2001;119:1077-9.
14. Detry-Morel M, Boschi A, Gehenot M, Geubel A. Bilateral transient visual obscurations with headaches during alpha 2 interferon therapy: a case report. Eur J Ophthalmol, 1995;5:271-4.
15. Louvet B, Sales MJ, Souid M, Barbanel C. Rétinopathie à l'interféron à propos d'un cas. J Fr Ophtalmol, 1997;20:624-7.
16. Michel JL, Valanconny C, Tchaplyguine F. Surveillance ophtalmologique des patients sous Interféron. Ann Dermato Venerol, 2001; 128:257-60.
17. Manesis EK, Moschos M, Brouzas D, Kotsiras J, Petrou C, Theodosiadis G et al. Neurovisual impairment: a frequent complication of alpha interferon treatment in chronic viral hepatitis. Hepatology, 1998;27:1441-2.
18. Perez-Alvarez AF, Jimenez-Alonso J, Reche-Molina I, Leon-Ruiz L, Hidalgo-Tenorio C, Sabio JM. Retinal vasculitis and vitreitis in a patient with chronic hepatitis C virus. Arch Intern Med, 2001;161:2262.
19. Tu KL, Bowyer J, Schofield K, Harding S. Severe interferon associated retinopathy. Br J Ophthalmol, 2003;87:247-8.
20. Loubière S, Ratily M, Moatti JP. Évaluation économique du dépistage et du traitement de l'hépatite C. Médecine/Sciences, 2002; 18:325-35.